02
Feb
Lagevrio, also know as molnupiravir, the medication for the oral treatment against COVID-19 that was authorized by the FDA in the United States (Food & Drug Administration), It could cause new changes in the virus with the potential for further spread. This was reported by a study conducted in the United States, in which the UK's Francis Crick Institute, Imperial College and the University of Liverpool collaborated, the results of which were published last week ahead of peer review. The pill, developed by Merck and Ridgeback Biotherapeutics, had gained FDA approval in December 2021 for at-risk adults who tested positive…
